Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tapentadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.82 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tapentadol SCHEMBL29611116 | 0.91 | OPRM1 (1.00) | SLC22A1OPRM1HIF1ALMNAKDM4E | |
| Tapentadol SCHEMBL146800 | 0.91 | OPRM1 (1.00) | SLC22A1OPRM1HIF1ALMNAKDM4E | |
| Tapentadol SCHEMBL147058 | 0.91 | OPRM1 (1.00) | SLC22A1OPRM1HIF1ALMNAKDM4E | |
| Tapentadol SCHEMBL116924 | 0.91 | OPRM1 (1.00) | SLC22A1OPRM1HIF1ALMNAKDM4E | |
| Tapentadol SCHEMBL16267561 | 0.91 | OPRM1 (1.00) | SLC22A1OPRM1HIF1ALMNAKDM4E | |
| Tapentadol SCHEMBL416917 | 0.91 | OPRM1 (1.00) | SLC22A1OPRM1HIF1ALMNAKDM4E | |
| Tapentadol SCHEMBL16266162 | 0.91 | OPRM1 (1.00) | SLC22A1OPRM1HIF1ALMNAKDM4E | |
| Tapentadol SCHEMBL1425181 | 0.91 | OPRM1 (1.00) | SLC22A1OPRM1HIF1ALMNAKDM4E | |
| Tapentadol SCHEMBL16267909 | 0.91 | OPRM1 (1.00) | SLC22A1OPRM1HIF1ALMNAKDM4E | |
| Tapentadol SCHEMBL3841350 | 0.91 | OPRM1 (1.00) | SLC22A1OPRM1HIF1ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105218386-B | Salts or co-crystals of 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol | 格吕伦塔尔有限公司 | 2021-07-06 | — | — | CN | disclosed |
| EP-3800179-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2021-04-07 | — | — | EP | disclosed |
| EP-3656765-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-27 | — | — | EP | disclosed |
| EP-3653600-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-20 | — | — | EP | disclosed |
| EP-3650439-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-13 | — | — | EP | disclosed |
| EP-3636629-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-04-15 | — | — | EP | disclosed |
| EP-3287447-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9133142-B2 | Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | GRUENENTHAL GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| EP-2595971-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20120022117-A1 | Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | GRUENENTHAL GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2012010316-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022117-A1 | Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | RCC2, EP300, SIGMAR1 | OPRM1 10/4885SLC6A2 199/4885SLC22A1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.